{"id":"W3211938324","doi":"10.1016/j.eururo.2021.10.001","title":"First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial","year":2021,"lang":"en","type":"article","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"University of Texas MD Anderson Cancer Center; Bristol-Myers Squibb; Ono Pharmaceutical; National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; European Society for Medical Oncology","keywords":"Medicine; Nivolumab; Sunitinib; Ipilimumab; Nephrectomy; Urology; Internal medicine; Second line; Kidney cancer; Renal cell carcinoma; Oncology; First line; Surgery; Kidney; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002447224,0.0006802211,0.002263254,0.0002146277,0.0002558073,0.0009411299,0.0005412156,0.000769716,0.001819252],"category_scores_gemma":[0.001512429,0.0002558244,0.002515552,0.0002257194,0.0003809163,0.0005035899,0.000276405,0.001691076,0.0002706063],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006662444,"about_ca_system_score_gemma":0.0008719453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004645142,"about_ca_topic_score_gemma":0.002209752,"domain_scores_codex":[0.9993197,0.0004646077,0.0000339931,0.0000704911,0.00004016225,0.00007112682],"domain_scores_gemma":[0.9991456,0.0003138595,0.0001882625,0.00007848847,0.00003980923,0.0002339008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.959062,0.002345094,0.005044383,0.0007710818,0.003339374,0.00008558838,0.00006286359,0.001284201,0.003896808,0.0001198618,0.001133242,0.02285545],"study_design_scores_gemma":[0.7929718,0.1625152,0.02921996,0.0001228019,0.005710175,0.0003573626,0.0000672282,0.003054164,0.002353082,0.0005722877,0.003008071,0.00004783022],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994083,0.004002708,0.0001683075,0.0002538559,0.0001323643,0.0002136566,0.0003319615,0.00002666039,0.0007874026],"genre_scores_gemma":[0.9965408,0.0009889279,0.0003151958,0.0003142387,0.0001474315,0.0002615793,0.0006930344,0.000007330004,0.0007314205],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002447224,"threshold_uncertainty_score":0.01294225,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03503532779758081,"score_gpt":0.2654187618524622,"score_spread":0.2303834340548813,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}